AssetMark’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
AssetMark's PTCT Position: Q3 2026 in Review
AssetMark opened a new position in PTC Therapeutics (PTCT) in Q3 2026: 24 shares worth $1.56K. The stake represents ﹤0.01% of the portfolio and ranks #3124 among its holdings. This is a return to the name: AssetMark previously reported a position in PTCT as recently as Q1 2026.
AssetMark first reported a position in PTCT in Q1 2020 and has held it in 7 quarters since. The position peaked at $2K in Q1 2021. 275 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.
- AssetMark held 24 shares of PTC Therapeutics worth $1.56K as of Q3 2026.
- PTC Therapeutics was a new AssetMark position in Q3 2026.
- PTC Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3124 holding.
- AssetMark first reported a position in PTC Therapeutics in Q1 2020 and has held it in 7 quarters since.
- AssetMark's PTC Therapeutics position peaked at $2K in Q1 2021.
- 275 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.